Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects

Expanded access Approved for marketing Supernus Pharmaceuticals, Inc.

Follow-on study to continue evaluation of the safety of OXC XR as adjunctive therapy in pediatric epilepsy

Evaluation	Drug	Modality	Dose	Route
Subject	Oxcarbazepine	Small molecule	—	—